The Second Oncogenic Hit Determines the Cell Fate of

B-cell childhood leukemia germline mouse models somatic transcription factors

Journal

Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250

Informations de publication

Date de publication:
2021
Historique:
received: 03 05 2021
accepted: 18 06 2021
entrez: 2 8 2021
pubmed: 3 8 2021
medline: 3 8 2021
Statut: epublish

Résumé

ETV6-RUNX1 is almost exclusively associated with childhood B-cell acute lymphoblastic leukemia (B-ALL), but the consequences of ETV6-RUNX1 expression on cell lineage decisions during B-cell leukemogenesis are completely unknown. Clinically silent ETV6-RUNX1 preleukemic clones are frequently found in neonatal cord blood, but few carriers develop B-ALL as a result of secondary genetic alterations. The understanding of the mechanisms underlying the first transforming steps could greatly advance the development of non-toxic prophylactic interventions. Using genetic lineage tracing, we examined the capacity of ETV6-RUNX1 to instruct a malignant phenotype in the hematopoietic lineage by cell-specific Cre-mediated activation of ETV6-RUNX1 from the endogenous

Identifiants

pubmed: 34336858
doi: 10.3389/fcell.2021.704591
pmc: PMC8320889
doi:

Types de publication

Journal Article

Langues

eng

Pagination

704591

Informations de copyright

Copyright © 2021 Rodríguez-Hernández, Casado-García, Isidro-Hernández, Picard, Raboso-Gallego, Alemán-Arteaga, Orfao, Blanco, Riesco, Prieto-Matos, García Criado, García Cenador, Hock, Enver, Sanchez-Garcia and Vicente-Dueñas.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Genet. 2014 Feb;46(2):116-25
pubmed: 24413735
Nat Rev Immunol. 2021 Feb 8;:
pubmed: 33558682
Nat Rev Cancer. 2018 Aug;18(8):471-484
pubmed: 29784935
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7
pubmed: 12048236
Nature. 2018 Mar 15;555(7696):371-376
pubmed: 29489755
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Bioinformatics. 2010 Aug 15;26(16):2069-70
pubmed: 20562413
Genome Biol. 2011;12(1):R1
pubmed: 21205303
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Science. 2008 Jan 18;319(5861):336-9
pubmed: 18202291
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Blood. 2020 Oct 29;136(18):2003-2017
pubmed: 32911536
Cancer Genet Cytogenet. 2001 Oct 15;130(2):93-104
pubmed: 11675129
Blood. 2018 Feb 15;131(7):821-826
pubmed: 29311095
Trends Immunol. 2021 May;42(5):371-374
pubmed: 33773925
Nat Immunol. 2015 Jul;16(7):766-774
pubmed: 25985233
Leukemia. 2015 Apr;29(4):839-46
pubmed: 25388957
Nat Commun. 2019 Dec 5;10(1):5563
pubmed: 31804490
Nature. 2007 Sep 27;449(7161):473-7
pubmed: 17851532
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Cancer Res. 2017 Aug 15;77(16):4365-4377
pubmed: 28630052
Cell. 2011 Apr 1;145(1):25-9
pubmed: 21458665
J Exp Med. 2011 Jun 6;208(6):1135-49
pubmed: 21606506
Nat Genet. 2017 Aug;49(8):1211-1218
pubmed: 28671688
Cancer Discov. 2015 Dec;5(12):1328-43
pubmed: 26408659
Cell Stem Cell. 2009 Jul 2;5(1):43-53
pubmed: 19570513
Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):174-80
pubmed: 25696852
Cancer Res. 2018 May 15;78(10):2669-2679
pubmed: 29490943
Oncotarget. 2017 Sep 27;8(60):102674-102680
pubmed: 29254279
Dev Cell. 2018 Feb 5;44(3):362-377.e7
pubmed: 29290585
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):255-60
pubmed: 24367082
Nat Rev Clin Oncol. 2019 Apr;16(4):227-240
pubmed: 30546053
Trends Cancer. 2018 Jun;4(6):408-417
pubmed: 29860985
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Cell. 1994 Dec 2;79(5):901-12
pubmed: 8001127
J Pharmacol Pharmacother. 2010 Jul;1(2):94-9
pubmed: 21350617
Neoplasia. 2013 Nov;15(11):1292-300
pubmed: 24339741
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13789-94
pubmed: 16940357
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590

Auteurs

Guillermo Rodríguez-Hernández (G)

Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
Institute for Biomedical Research of Salamanca, Salamanca, Spain.

Ana Casado-García (A)

Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
Institute for Biomedical Research of Salamanca, Salamanca, Spain.

Marta Isidro-Hernández (M)

Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
Institute for Biomedical Research of Salamanca, Salamanca, Spain.

Daniel Picard (D)

Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.

Javier Raboso-Gallego (J)

Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
Institute for Biomedical Research of Salamanca, Salamanca, Spain.

Silvia Alemán-Arteaga (S)

Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
Institute for Biomedical Research of Salamanca, Salamanca, Spain.

Alberto Orfao (A)

Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Servicio de Citometría, Departamento de Medicina, CIBERONC (CB16/12/00400), and Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.

Oscar Blanco (O)

Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Departamento de Anatomía Patológica, Universidad de Salamanca, Salamanca, Spain.

Susana Riesco (S)

Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Department of Pediatrics, Hospital Universitario de Salamanca, Salamanca, Spain.

Pablo Prieto-Matos (P)

Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Department of Pediatrics, Hospital Universitario de Salamanca, Salamanca, Spain.

Francisco Javier García Criado (FJ)

Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.

María Begoña García Cenador (MB)

Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Departamento de Cirugía, Universidad de Salamanca, Salamanca, Spain.

Hanno Hock (H)

Cancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, Harvard Medical School, and Harvard Stem Cell Institute, Boston, MA, United States.

Tariq Enver (T)

Department of Cancer Biology, UCL Cancer Institute, University College London, London, United Kingdom.

Isidro Sanchez-Garcia (I)

Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas/Universidad de Salamanca, Salamanca, Spain.
Institute for Biomedical Research of Salamanca, Salamanca, Spain.

Carolina Vicente-Dueñas (C)

Institute for Biomedical Research of Salamanca, Salamanca, Spain.
Department of Pediatrics, Hospital Universitario de Salamanca, Salamanca, Spain.

Classifications MeSH